DaVita Inc. to Participate in TD Cowen's 46th Annual Health Care Conference [Accessibility Statement] Skip NavigationDENVER, Feb. 24, 2026 /PRNewswire/ -- [DaVita Inc.](NYSE: DVA) today announced that its chief financial officer, Joel Ackerman, and its group vice president of investor relations, Nic Eliason, will participate in a fireside chat with investors at TD Cowen's 46th Annual Health Care Conference on Monday, March 2, 2026 at 11:50 am EST.To view the live webcast, visit the TD Cowen page [here] and ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 1-14106 DAVITA INC. (Exact name of registrant as specified in charter) Delaware 51-0354549 (State of incorporation) (I.R.S. ...

Core Viewpoint - Berkshire Hathaway has two strong investment opportunities in DaVita and Kraft Heinz, while UnitedHealthcare Group is currently not recommended for investment. Group 1: DaVita (DVA) - DaVita has been a long-term investment for Berkshire Hathaway since 2011 and is showing signs of recovery after beating quarterly expectations and providing optimistic 2026 earnings guidance [5][7]. - The current stock price of DaVita is $140.71, with a market cap of $9.9 billion and a gross margin of 27% [6][7]. - DaVita's earnings per share for the year are expected to be between $13.60 and $15, suggesting it is trading at a low multiple of around 9 times forward earnings, compared to its historical range of 13 to 14 times [8]. Group 2: Kraft Heinz (KHC) - Berkshire Hathaway holds a 27% stake in Kraft Heinz, valued at approximately $7.5 billion, but has faced significant losses on this investment and may consider selling part of its stake [9][10]. - Kraft Heinz is currently trading at about 9 times forward earnings, which is a discount compared to its peers, presenting a potential opportunity for new investors [11]. - The company plans to split into two entities to unlock value, similar to Kellogg's successful separation in 2023, which could enhance shareholder value [12]. Group 3: UnitedHealthcare Group (UNH) - Berkshire Hathaway purchased 5 million shares of UnitedHealthcare Group, but the stock has faced challenges due to lower-than-expected Medicare Advantage payment increases, leading to a drop in stock price from $350 to around $280 [13][14]. - UnitedHealthcare currently trades at 16 times forward earnings, which is a premium compared to peers, indicating potential for further multiple compression as the company's growth narrative is under pressure [15].

Core Viewpoint - DaVita Inc. reported strong fourth-quarter earnings and provided optimistic guidance for fiscal 2026, leading to a significant increase in stock price [1]. Earnings Summary - Adjusted earnings were $3.40 per share, surpassing the consensus estimate of $3.16 [2]. - Sales reached $3.62 billion, reflecting a year-over-year increase of 5.8% and exceeding the consensus of $3.497 billion [2]. - Revenue per treatment increased from $410.59 to $422.60, driven by higher average reimbursement rates and seasonal factors [2]. Year-to-Date Changes - The year-to-date performance was influenced by the inclusion of phosphate binders in the ESRD Prospective Payment System and annual increases in average reimbursement rates, including Medicare [3]. - Total U.S. dialysis treatments for Q4 2025 were 7,264,520, averaging 91,608 treatments per day, which is a slight decrease of 0.1% from Q3 2025 [3]. Cost and Treatment Growth - Normalized non-acquired treatment growth for Q4 2025 compared to Q4 2024 was down by 0.6% [4]. - Patient care costs per treatment rose from $273.54 to $279.60, primarily due to increased health benefit expenses and medical supply costs [4]. Guidance - For fiscal 2026, DaVita anticipates adjusted earnings between $13.60 and $15.00 per share, exceeding the consensus of $12.65 [5]. - Adjusted operating income is expected to range from $2.09 billion to $2.24 billion, with treatment volume projected to remain flat compared to 2025 [5]. - Revenue per treatment is expected to grow by approximately 1% to 2%, while cost growth is anticipated to be between 1.25% and 2.25% [5]. Additional Investments - DaVita's CFO mentioned an estimated $40 million headwind from the expiration of enhanced premium tax credits, which is offset by the removal of a $45 million headwind from a previous cyber incident [6]. - DaVita is making a minority investment of approximately $200 million in Elara Caring, which is expected to positively impact other income lines [7]. Analyst View - Barclays has maintained an Equal-Weight rating on DaVita and raised the price target from $143 to $158 [8]. - Following the earnings report, DaVita's stock rose by 21.69% to $135.31 [8].

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 1% on Tuesday.The Dow traded down 0.19% to 49,316.23 while the NASDAQ dipped 1.23% to 23,302.18. The S&P 500 also fell, dropping, 0.62% to 6,933.29.Check This Out: How To Earn $500 A Month From Goldman Sachs Stock Ahead Of Q4 EarningsLeading and Lagging SectorsMaterials shares gained by 1.8% on Tuesday.In trading on Tuesday, information technology stocks fell by 1.9%.Top HeadlineOn Tuesday, Pfizer Inc. (NYSE:PFE) sh ...

Core Insights - DaVita Inc. (DVA) reported adjusted earnings per share (EPS) of $3.40 for Q4 2025, a 51.8% increase year over year, exceeding the Zacks Consensus Estimate by 5.1% [1] - The company's total revenues for Q4 2025 reached $3.62 billion, reflecting a 9.9% year-over-year increase and surpassing the Zacks Consensus Estimate by 2.7% [2] - Full-year adjusted EPS was $10.78, marking an 11.4% increase from the previous year, also beating the Zacks Consensus Estimate by 0.7% [1][4] Revenue Analysis - Revenue per treatment (RPT) in Q4 2025 was $422.6 million, up 6.8% year over year and 2.9% sequentially, driven by resolution of aged receivables and improved yield [3] - Full-year revenues totaled $13.64 billion, a 6.5% improvement from the prior year, exceeding the Zacks Consensus Estimate by 0.7% [4] Segment Performance - Dialysis patient service revenues were $3.39 billion in Q4 2025, an 8.9% increase year over year, while other revenues reached $220.6 million, up 25.7% from the previous year [5] Treatment Volume and Patient Base - DaVita provided dialysis services to approximately 295,000 patients across 3,242 outpatient dialysis centers as of December 31, 2025 [6] - Total U.S. dialysis treatments for Q4 were 7,264,520, averaging 91,608 per day, which represents a slight sequential decrease of 0.1% [6] Financial Metrics - Gross profit for Q4 increased by 13.2% year over year to $1.21 billion, with gross margin expanding by 98 basis points to 33.4% [9] - Adjusted operating profit totaled $737.9 million, reflecting a 12.7% increase from the prior year, with adjusted operating margin expanding to 20.4% [11] Cash Flow and Debt - DaVita ended Q4 2025 with cash and cash equivalents of $700.7 million, a slight decrease from $736.5 million at the end of Q3 [12] - Total debt at the end of Q4 was $10.27 billion, up from $10.25 billion at the end of Q3 [12] Share Repurchase - During Q4 2025, DaVita repurchased 2.7 million shares for $331 million, with an additional 1.7 million shares repurchased for $200 million from January 1 to February 2, 2026 [13] Guidance - For 2026, DaVita expects RPT growth of 1%-2% and adjusted EPS in the range of $13.60-$15.00, with the Zacks Consensus Estimate currently at $12.89 [14] Strategic Initiatives - DaVita announced a strategic clinical partnership with Elara Caring to enhance its end-stage kidney disease offerings, aiming to reduce hospitalizations and improve patient experience [16]

分组1: Pterodine - Pterodine reported better-than-expected quarterly results, with adjusted EPS at $1.80 and revenue at $1.08 billion, surpassing street expectations [2][4] - The company experienced its first billion-dollar quarter since 2021, indicating a significant cyclical structural rebound [4] - Guidance for Q1 revenue is projected between $1.15 billion and $1.4 billion, with EPS guidance between $1.89 and $2.25, both exceeding market expectations [5][4] - Pterodine is recognized as a core player in the AI sector, benefiting from increased demand for AI-related chips across various applications [3][6] 分组2: Dvita - Dvita's quarterly results showed strong performance with adjusted EPS of $3.40 and revenue of $3.62 billion, both exceeding street forecasts [8][9] - The company anticipates a bullish outlook for 2026, with adjusted EPS guidance between $13.60 and $15.00, reflecting confidence in reimbursement trends and operational momentum [8][9] - Dvita's results were supported by steady demand for kidney dialysis services and improved reimbursement rates, although they are still addressing operational challenges from a ransomware attack [9][10] 分组3: Pepsi - Pepsi reported adjusted EPS of $2.26 and revenue of $29.34 billion, both beating market expectations [12] - The company is experiencing volume softness in North America, with global food volume declining by 2%, while beverage volume increased by 1% [12][13] - Pepsi is implementing a pricing strategy shift, including planned price cuts, and expanding into protein-based snacks and functional drinks to meet changing consumer demands [13][14]

Core Viewpoint - The article discusses the investment positions held by the author in specific companies, indicating a long position in DVA and FMS, which may suggest a positive outlook on these stocks [1]. Group 1: Company Disclosures - The author has a beneficial long position in the shares of DVA and FMS, either through stock ownership, options, or other derivatives [1]. - The article expresses the author's personal opinions and does not involve compensation from the companies mentioned [1]. Group 2: Investment Considerations - The article emphasizes that it should not be considered financial advice, as the author is not a licensed financial advisor [2]. - Investors are encouraged to conduct their own due diligence and research prior to making any investment decisions [2]. - The article highlights the risks associated with short-term trading, options trading, and futures trading, which may not be suitable for all investors [2].

Analyst’s Disclosure: I/we have a beneficial long position in the shares of DVA, FMS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. While this article may sound like financial advice, please observe that the author is not a CFA or in any way licensed to give financial a ...

Core Viewpoint - DaVita's stock price increased by 17.8% on February 3rd [2] Company Summary - DaVita experienced a significant stock price rise, indicating positive market sentiment or potential favorable developments [2]